-
After trial win, Lilly's Mounjaro primed for expansion in kids 10-17 with type 2 diabetes
18 Sep 2025 17:31 GMT
… indication for the juggernaut diabetes medication.
“Youth living with … 3.
Additionally, in the trial’s extension study, the … Mounjaro—who discontinued treatment.
GLP-1 drugs previously approved for … AstraZeneca’s Bydureon. All were endorsed by the FDA between …
-
Semaglutide Could Offer Potential Treatment for Cocaine Use Disorder
14 Sep 2025 16:25 GMT
… Disorder Treatment
Previous research has identified that exenatide (Bydureon; AstraZeneca … first trial showing semaglutide’s potential as a drug … the challenges of identifying medications for stimulant use … findings should encourage clinical trials of GLP-1 …
-
FDA's green list cracks down on illegal imported drug ingredients
05 Sep 2025 22:51 GMT
… -1 drugs, some of which are older medications, include Adlyxin, Byetta, Bydureon, Retatrutide … is their product.
Previously, the FDA identified serious concerns about compound …
-
January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
29 Aug 2025 20:22 GMT
… (GLP-1) analogues
Adlyxin (lixisenatide)
Bydureon (exenatide)
Bydureon BCise (exenatide)
Byetta (exenatide … based on available information.
A FDA Drug Safety Communication was issued on … Information", and "Medication Guide" sections of the …
-
July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
29 Aug 2025 20:22 GMT
… ) analogues
Adlyxin (lixisenatide)
Bydureon (exenatide)
Bydureon BCise (exenatide)
Byetta (exenatide … (ocrelizumab)
Myocardial infarction
FDA determined that no action is … Sunosi (solriamfetol hydrochloride)
Hypersensitivity
FDA determined that no action is …
-
GLP-1 Drugs Market Outlook: Expanding Patient Pool, FDA Approvals, And Robust Pipeline Fuel Growth To 2034 Delveinsight
21 Aug 2025 00:37 GMT
… pools, current treatment practices, emerging drugs, and market … clinical trial.
In August 2025, the FDA warned … (dulaglutide), BYETTA/BYDUREON (exenatide), VICTOZA (liraglutide), … Therapeutics (VK2735), Terns Pharmaceuticals (TERN-601), and Eccogene …
-
13 Questions to Ask Your Doctor Before Starting a GLP-1 Weight Loss Drug
06 Aug 2025 23:35 GMT
… . Sold as Byetta or Bydureon, this injectable medication is used to treat … obesity treatment under the brand name Zepbound, while semaglutide, the medication approved … Ask Your Doctor Before Starting a GLP-1 Weight Loss Drug originally …
-
Weekly GLP-1s Significantly Reduce Cardiovascular Risks
18 Sep 2025 20:53 GMT
… and increased evidence of these drugs’ unprecedented impacts, researchers have … include extended-release (ER) exenatide (Bydureon), dulaglutide (Trulicity), semaglutide (Ozempic), and … the US FFS Medicare population with T2D and ASCVD, treatment with OW …
-
Nearly 17 Million Young Americans Could Benefit From Ozempic-like Drugs
04 Aug 2025 16:00 GMT
… were appropriate candidates for these medications could receive them after shared … Wegovy), liraglutide (Saxenda and Victoza), Bydureon BCise (exenatide), Trulicity (dulaglutide) and … .S. Food and Drug Administration criteria for GLP-1RA treatment.
Over-the …
-
New kidney injury warnings added to all GLP-1 drugs by FDA
24 Jul 2025 08:04 GMT
… present during clinical trial stages. In this … 1 products – Byetta, Bydureon BCISE, Mounjaro, Saxenda … blood-cleaning hemodialysis treatment. Dehydration causes … drugs are potent medications that require monitoring, especially in vulnerable patients.
The FDA …
About
© 1995-2025